Impact of rosuvastatin on atherosclerosis in people with HIV at moderate cardiovascular risk: a randomised, controlled trial.

Details

Serval ID
serval:BIB_6652223060C9
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Impact of rosuvastatin on atherosclerosis in people with HIV at moderate cardiovascular risk: a randomised, controlled trial.
Journal
AIDS
Author(s)
Trevillyan J.M., Dart A., Paul E., Cavassini M., Fehr J., Staehelin C., Dewar E.M., Hoy J.F., Calmy A.
ISSN
1473-5571 (Electronic)
ISSN-L
0269-9370
Publication state
Published
Issued date
15/03/2021
Peer-reviewed
Oui
Volume
35
Number
4
Pages
619-624
Language
english
Notes
Publication types: Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Abstract
People living with HIV-1 (PLHIV) are at increased risk for cardiovascular disease.
This study aimed to determine if PLHIV would benefit from starting statins at a lower threshold than currently recommended in the general population.
A double-blind multicentre, randomised, placebo-controlled trial was performed.
Participants (n = 88) with well controlled HIV, at moderate cardiovascular risk (Framingham score of 10-15%), and not recommended for statins were recruited from Australia and Switzerland. They were randomized 1 : 1 to rosuvastatin (n = 44) 20 mg daily, 10 mg if co-administered with ritonavir/cobicistat-boosted antiretroviral therapy, or placebo (n = 40) for 96 weeks. Assessments including fasting blood collection and carotid--intima media thickness (CIMT) were performed at baseline, and weeks 48 and 96. The primary outcome was the change from baseline to week 96 in CIMT (clinicaltrials.gov: NCT01813357).
Participants were predominantly men [82 (97.6%); mean age 54 years (SD 6.0)]. At 96 weeks, there was no difference in the progression of CIMT between the rosuvastatin (mean 0.004 mm, SE 0.0036) and placebo (0.0062 mm, SE 0.0039) arms (P = 0.684), leading to no difference in CIMT levels between groups at week 96 [rosuvastatin arm, 0.7232 mm (SE 0.030); placebo arm 0.7785 mm (SE 0.032), P = 0.075].Adverse events were common (n = 146) and predominantly in the rosuvastatin arm [108 (73.9%)]. Participants on rosuvastatin were more likely to cease study medication because of an adverse event [7 (15.9%) vs. 2 (5.0%), P = 0.011].
In PLHIV, statins prescribed at a lower threshold than guidelines did not lead to improvements in CIMT but was associated with significant adverse events.
Keywords
Atherosclerosis/complications, Atherosclerosis/drug therapy, Australia, Cardiovascular Diseases/prevention & control, Carotid Intima-Media Thickness, Double-Blind Method, HIV Infections/complications, HIV Infections/drug therapy, Heart Disease Risk Factors, Humans, Male, Middle Aged, Risk Factors, Rosuvastatin Calcium, Switzerland, Treatment Outcome
Pubmed
Web of science
Open Access
Yes
Create date
07/12/2020 15:57
Last modification date
22/07/2022 6:38
Usage data